期刊
CANCER LETTERS
卷 490, 期 -, 页码 31-43出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.05.032
关键词
Hypoxia-sensitive; Drug delivery; Cancer therapy; Bioreduction; Controlled release
类别
资金
- Korea Research Fellowship (KRF) Program of the National Research Foundation (NRF), Republic of Korea [2019H1D3A1A01071101]
- Basic Science Research Programs of the National Research Foundation (NRF), Republic of Korea [2019R1I1A1A01061426, 2018R1A2B3006080]
- National Research Foundation of Korea [2019R1I1A1A01061426, 2019H1D3A1A01071101, 2018R1A2B3006080] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Hypoxia is a negative prognostic indicator of solid tumors. Increasing evidence indicates that the intratumoral hypoxic microenvironment is strongly related to enhanced tumor aggressiveness, decreased therapeutic effect and poor prognosis of chemotherapy, radiotherapy (RT), and photodynamic therapy (PDT). However, due to an unusual gene expression profile and abnormal metabolism, enzymes responsible for reduction reactions or electron donation are highly reactive in hypoxic tumor cells and provide the possibility of exploiting targeted drug delivery systems for cancer therapy. Taking advantage of the specific bioreductive microenvironments in hypoxic tumors, researchers have recently developed several hypoxia-responsive nanoparticles (HR-NPs) for targeted cancer therapy. In this review, the hypoxia-responsive molecular structures that were employed to construct HR-NPs are presented. Furthermore, the strategies to make use of these HR-NPs, and the recent advances in HR-NPs for efficient tumor-targeted drug delivery and cancer therapy are highlighted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据